{"id":257,"date":"2023-05-10T10:00:00","date_gmt":"2023-05-10T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=257"},"modified":"2025-09-08T10:09:53","modified_gmt":"2025-09-08T10:09:53","slug":"china-bd-2023-zion-pharma-and-roche-enters-a-680-million-usd-acquisition-on-her2-tki-zn-a-1041-rg6596","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/257.html","title":{"rendered":"[China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)"},"content":{"rendered":"\n<p>Announced Date: 2023-05-09 (May 9, 2023)<\/p>\n\n\n\n<p>Asset Name: ZN-A-1041 (RG6596, perzebertinib)<\/p>\n\n\n\n<p>Licensor (Seller): Zion Pharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Roche<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptor 2 (HER2).<\/p>\n\n\n\n<p>Potential Indication: HER2-positive breast cancer (HER-2+ BC)<\/p>\n\n\n\n<p>Current Stage: Phase I<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Roche has acquired the global rights to Zion\u2019s lead program, ZN-A-1041.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Zion will receive<\/p>\n\n\n\n<p>Upfront payment and near-term milestone payments up to $70 million,<\/p>\n\n\n\n<p>Development, regulatory, and sales-based milestone  payments of up to $610 million.<\/p>\n\n\n\n<p>Tiered royalties on sales.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.zionpharma.com\/newsinfo\/5887062.html\">Zion Pharma Announces Global Agreement with Roche to develop and commercialize a blood brain barrier penetrant oral HER2 tyrosine kinase inhibitor-\u82cf\u5dde\u8d5e\u8363\u533b\u836f\u79d1\u6280\u6709\u9650\u516c\u53f8<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Zion Pharma, \u8d5e\u8363\u533b\u836f<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-05-09 (May 9, 2023) Asset Name: ZN-A-1041 (RG6596, perzebertinib) Licensor (Seller): Zion Pharma (China) &hellip; <a title=\"[China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/257.html\"><span class=\"screen-reader-text\">[China BD 2023] Zion Pharma and Roche enters a 680 million USD acquisition on HER2 TKI ZN-A-1041 (RG6596)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-257","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=257"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/257\/revisions"}],"predecessor-version":[{"id":258,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/257\/revisions\/258"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}